ObsEva SA (OBSV)

[Frankestin]

Feb. 01, 2022 (GLOBE NEWSWIRE) -- ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the appointment of Katja Buhrer as Chief Strategy Officer and member of the company’s Executive Committee, effective February 1, 2022. Ms. Buhrer will oversee a range of operational areas including corporate strategy, investor relations and public relations, and will contribute in other areas such as business development and alliance management.

“We are thrilled to welcome Katja to ObsEva at this important time in the company’s growth,” said Brian O’Callaghan, Chief Executive Officer of ObsEva. “Katja is an accomplished corporate development executive whose track record managing strategic transactions, partnerships, and investor relations programs strengthens our leadership team as we prepare to transition to a commercial-stage company. We further look forward to her leadership as we explore new indications, partnerships, and other strategic opportunities that enhance ObsEva’s value.”

Ms. Buhrer commented, “I am delighted to join ObsEva and collaborate with the executive team to address large, underserved indications that compromise women’s reproductive health. ObsEva’s regulatory, clinical, and strategic advances in the past year, coupled with upcoming catalysts as the company pursues multiple approvals in 2022, make this a compelling opportunity. I look forward to working towards real change in women’s health while enhancing value for our shareholders.”